E. Liu

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma

Guoan Chen, Ying Cheng, Wei Li, 2020, Journal of Hematology & Oncology.

Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy

Yun-Ju Huang, Min Li, H. Issafras, 2021, PloS one.

Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy

H. Issafras, Chi-Ling Tseng, Weidong Jiang, 2021, Expert opinion on biological therapy.

Global clinical trials validating bioequivalence with China-manufactured trastuzumab biosimilar, HLX02, and trastuzumab.

I. Bondarenko, A. Luk, W. Li, 2018, Annals of Oncology.

First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer

Bing-he Xu, I. Bondarenko, Q. Wang, 2019, Annals of Oncology.

First china-manufactured proposed rituximab biosimilar met primary efficacy and safety endpoints in CD20-positive diffuse large B-cell lymphoma (generics).

A. Luk, W. Li, W. Jiang, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck

A. Luk, H. Lin, C. Ho, 2019, Annals of Oncology.

A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy

T. Chao, A. Luk, C-L. Chang, 2019, Annals of Oncology.

FRI0086 CHINA-MANUFACTURED ADALIMUMAB BIOSIMILAR, HLX03, DEMONSTRATED PHARMACOKINETIC EQUIVALENCE AND COMPARABLE SAFETY TO REFERENCE ADALIMUMAB

He Gao, Yanhua Ding, A. Luk, 2019, Poster Presentations.